First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas

First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas

Pancreatic β-cell mass (BCM) has a central importance in the pathophysiology of diabetes mellitus. Recently, pancreatic β-cell-specific imaging, especially positron emission tomography (PET) with exendin-based probes, has emerged for non-invasive evaluation of BCM. We developed a novel exendin-based...

Full description

Bibliographic Details
Main Authors: Hiroyuki Fujimoto, Naotaka Fujita, Keita Hamamatsu, Takaaki Murakami, Yuji Nakamoto, Tsuneo Saga, Takayoshi Ishimori, Yoichi Shimizu, Hiroyuki Watanabe, Kohei Sano, Norio Harada, Hiroshi Nakamura, Kentaro Toyoda, Hiroyuki Kimura, Shunsaku Nakagawa, Mitsuharu Hirai, Atsushi Murakami, Masahiro Ono, Kaori Togashi, Hideo Saji, Nobuya Inagaki
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Endocrinology
Subjects:
β-cell imaging
exendin-4
glucagon-like peptide-1 receptor (GLP-1R)
PET
first-in-human study
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.717101/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.717101/full

Similar Items